{"company": "Novartis", "source": "Manual Map - Novartis", "stats": {"entities": 72, "matched": 5, "snippets": 29}, "root": {"id": "novartis-rd", "name": "Novartis Research & Development", "type": "company", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "biomedical-research", "name": "Biomedical Research", "type": "division", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 9, "teamSizes": [], "sizeMentions": [], "snippets": [{"quote": "centralized services across the, all biomedical research in novartis", "date": "2025-11-11", "gongUrl": "https://app.gong.io/call?id=2414cb1b14350c13bcc8c1db5ba43b37822b50dd48f16100ff0cba8182771b36", "callId": "2025-11-11_2414cb1b1435", "customerName": "Petra Simic", "internalName": "Tim Fung", "customerEmail": "petra.simic@novartis.com", "internalEmail": "tim@biorender.com", "speakerId": "6048279280409577254", "sizeMentions": [], "contextBefore": "...[Speaker 6048279280409577254]: And as soon as I have a new name, I'll forward that one to you.\n[Speaker 6048279280409577254]: Okay?\n[Speaker 6048279280409577254]: And then we hopefully have a smooth transition.\n[Speaker 6048279280409577254]: But even if I'm transitioning, I mean, even if I'm leaving first of December, I will most likely December January, I will still be with one leg in IMM because I assume we will not have transition.\n[Speaker 6048279280409577254]: Yeah, exactly.\n[Speaker 6048279280409577254]: Doing two jobs at the same time as usual.\n[Speaker 6048279280409577254]: Yeah.\n[Speaker 596451315459775802]: What are you transitioning to?\n[Speaker 6048279280409577254]: I'm going to sciops scientific operations.\n[Speaker 6048279280409577254]: Oh, okay.\n[Speaker 6048279280409577254]: I don't know if you've been in touch with them.\n[Speaker 6048279280409577254]: So that's the more, yeah.\n[Speaker 6048279280409577254]: Yeah, that's the department really being more responsible for ", "contextAfter": ".\n[Speaker 6048279280409577254]: And I'm gonna leading team looking at everything related to lab equipment, lab supplies, lab solution services, for BR globally.\n[Speaker 6048279280409577254]: So that's quite a bit of a different role.\n[Speaker 6048279280409577254]: But I'm looking forward to that.\n[Speaker 6048279280409577254]: Yeah.\n[Speaker 596451315459775802]: Oh, nice.\n[Speaker 596451315459775802]: Nice.\n[Speaker 596451315459775802]: Okay.\n[Speaker 596451315459775802]: Yeah.\n[Speaker 596451315459775802]: Oh, congratulations.\n[Speaker 596451315459775802]: Thank you.\n[Speaker 596451315459775802]: Must be very exciting.\n[Speaker 6048279280409577254]: Yeah, it's going to be a challenge.\n[Speaker 596451315459775802]: No, that sounds that's quite different then.\n[Speaker 596451315459775802]: Is it?\n[Speaker 596451315459775802]: So sciops oversees all of BR, is that it?\n[Speaker 6048279280409577254]: Yes, it's like, yeah, yes.\n[Speaker 6048279280409577254]: I said centralized service.\n[S...", "callTitle": "BioRender | Novartis - IMM - check-in"}, {"quote": "put together licensing models for specific groups within biomedical research", "date": "2025-11-05", "gongUrl": "https://app.gong.io/call?id=cebf2186536fb0a794dd7ed70022fed95b6107edc9abf012ee6cc8b981a91bc9", "callId": "2025-11-05_cebf2186536f", "customerName": "Renee Bergeron", "internalName": "Ross Proudfoot; Sofiya Medvezhonkova", "customerEmail": "renee.bergeron@novartis.com", "internalEmail": "ross@biorender.com; sofiya.m@biorender.com", "speakerId": "2984491289675242830", "sizeMentions": [], "contextBefore": "... rainy.\n[Speaker 2984491289675242830]: Yeah, we held on nice for a while in October.\n[Speaker 2984491289675242830]: It was sunny but.\n[Speaker 3699100416717219889]: it was, we had a really nice fall this year as well.\n[Speaker 3699100416717219889]: I'm from New Orleans.\n[Speaker 3699100416717219889]: So I grew up without fall without anything other than summer and hotter summer, but yeah, I appreciate the four seasons.\n[Speaker 2984491289675242830]: Yeah, it's nice.\n[Speaker 2984491289675242830]: It's nice.\n[Speaker 2984491289675242830]: It makes you that much happier when spring hits, right?\n[Speaker 3699100416717219889]: Yeah, for sure.\n[Speaker 3699100416717219889]: It's.\n[Speaker 2984491289675242830]: enjoyable.\n[Speaker 2984491289675242830]: So, Sophia did fill me in on your short conversation regarding biorender.\n[Speaker 2984491289675242830]: I've been managing the novartis account for gosh, over two years.\n[Speaker 2984491289675242830]: At least now, we've been able to sort of ", "contextAfter": ".\n[Speaker 2984491289675242830]: So, a number of them have sort of open access to biorender along with that.\n[Speaker 2984491289675242830]: There is some central licensing available for those that need like individual licenses.\n[Speaker 2984491289675242830]: But I have been in touch with somebody in PCS, tuya, who helped us put together.\n[Speaker 2984491289675242830]: I think the demonstration that you're a part of.\n[Speaker 3699100416717219889]: And who is that?\n[Speaker 3699100416717219889]: I'm sorry?\n[Speaker 2984491289675242830]: But tuya, is her name.\n[Speaker 2984491289675242830]: I can send you her contact as well.\n[Speaker 2984491289675242830]: But I think we're at the point now where we're getting some interest for sure.\n[Speaker 2984491289675242830]: At PCS, they could definitely evaluate using biorender as more of like an organizational tool for the department where everyone has access is able to collaborate and sort of use biorender as their way to communicate with slide d...", "callTitle": "BioRender & Novartis - Follow Up Call"}, {"quote": "Is that across all of biomedical research?", "date": "2025-07-04", "gongUrl": "https://app.gong.io/call?id=8e4009585731cfafa3e9eafd1b9b09f5ee3d12a80df4ee555644aa6d7d7effe6", "callId": "2025-07-04_8e4009585731", "customerName": "Zuni Bassi", "internalName": "Ross Proudfoot", "customerEmail": "zuni.bassi@novartis.com", "internalEmail": "ross@biorender.com", "speakerId": "2355354121190058325", "sizeMentions": [], "contextBefore": "...sometimes we can share our work and prepare posters.\n[Speaker 3626252761295043604]: So it's something that happens sometimes.\n[Speaker 3626252761295043604]: Yes, I would say the most regular thing is presentation that's every day.\n[Speaker 3626252761295043604]: And even just for that, I like to be able to explain things with figures.\n[Speaker 3626252761295043604]: So, I, that's why I think that I would use this.\n[Speaker 2355354121190058325]: Yeah, yeah.\n[Speaker 2355354121190058325]: That's that's a typical sort of pathway.\n[Speaker 2355354121190058325]: So I'll make sure because I know we're coming up on time that we kind of show the illustration piece the most for your like internal science day.\n[Speaker 2355354121190058325]: Is that an immunology type day or is that across all of VR?\n[Speaker 3626252761295043604]: Say, again, I didn't understand.\n[Speaker 2355354121190058325]: Is that sort of science day where you're presenting some of these posters?\n[Speaker 2355354121190058325]: ", "contextAfter": "\n[Speaker 3626252761295043604]: It can, it can be both.\n[Speaker 3626252761295043604]: No, it usually, it's broader than just immunology.\n[Speaker 3626252761295043604]: So it's kind of VR level or Basel VR.\n[Speaker 3626252761295043604]: Yeah.\n[Speaker 2355354121190058325]: And is there like a particular time of year that you guys, I'm just asking because we can also support especially with everyone having access.\n[Speaker 2355354121190058325]: Is we could do like a poster sort of training or something like a month before that?\n[Speaker 3626252761295043604]: Usually these things, these events usually tend to happen in spring, okay?\n[Speaker 3626252761295043604]: But then, you know, conferences are all scattered here, yeah.\n[Speaker 2355354121190058325]: Awesome.\n[Speaker 2355354121190058325]: Well, yeah, no, I think, I mean there's a few ways.\n[Speaker 2355354121190058325]: I think ultimately, if you're getting comfortable in the illustrator which is sort of what you've probably seen u...", "callTitle": "BioRender & Novartis - Intro Call : Zuni Bassi"}, {"quote": "I'm part of nibr, but they changed the name to the biomedical research", "date": "2025-02-19", "gongUrl": "https://app.gong.io/call?id=c8792a337b0a52bb5b1aaac29b88ffc414647107b7b5b689a4920ab0d391a116", "callId": "2025-02-19_c8792a337b0a", "customerName": "Rongqiang Yang", "internalName": "Jaden Dankevy", "customerEmail": "rongqiang.yang@novartis.com", "internalEmail": "jaden.dankevy@biorender.com", "speakerId": "7926109428293961304", "sizeMentions": [], "contextBefore": "...Speaker 1260641522862927321]: We actually, we've been obviously in contact with novartis central.\n[Speaker 1260641522862927321]: It for a long time now, and as of just a few weeks ago, novartis central license is now actually available for everybody throughout novartis and we've actually signed a legal agreement with a company.\n[Speaker 1260641522862927321]: Yeah, so that anybody who is curious about getting supported, can now look into it, but let me ask you, are you not a part?\n[Speaker 1260641522862927321]: Because before it was just for nibr, the biomedical institute.\n[Speaker 7926109428293961304]: Huh.\n[Speaker 7926109428293961304]: Oh,\n[Speaker 7926109428293961304]: oh, I see.\n[Speaker 7926109428293961304]: Yeah.\n[Speaker 7926109428293961304]: So, right now, it's biomedical research.\n[Speaker 1260641522862927321]: So, now, it's the whole company, but what department are you a part of you're?\n[Speaker 1260641522862927321]: Not part of nibr, are you?\n[Speaker 7926109428293961304]: ", "contextAfter": ".\n[Speaker 7926109428293961304]: There's.\n[Speaker 7926109428293961304]: No, Ni, it's just the biomedical research VR.\n[Speaker 7926109428293961304]: Yeah.\n[Speaker 1260641522862927321]: Oh, it's just biomedical research.\n[Speaker 1260641522862927321]: Okay?\n[Speaker 1260641522862927321]: It's just BR now.\n[Speaker 1260641522862927321]: Yeah.\n[Speaker 1260641522862927321]: And are you part of a specific group within nibr?\n[Speaker 1260641522862927321]: Are you part of a specific department or disease area?\n[Speaker 7926109428293961304]: Yeah, we are under the CGT.\n[Speaker 7926109428293961304]: So the B, let's say biologic center and there's a CGT sub team, so, but it's still under the, but, yeah, it's still under the BR.\n[Speaker 7926109428293961304]: So it's yeah, yeah.\n[Speaker 1260641522862927321]: Ah, you're part of the, and you're part of the biologic center?\n[Speaker 1260641522862927321]: Okay.\n[Speaker 1260641522862927321]: Yeah, I spoke to some people from the biologic center ...", "callTitle": "Call with Novartis - Rongqiang Yang"}, {"quote": "I'm part of the biomedical research because BR umbrella.", "date": "2025-01-10", "gongUrl": "https://app.gong.io/call?id=9e7222a482fb050fd6ee6838be736f9284bf15a1a14b3229206f6f355fc1ace8", "callId": "2025-01-10_9e7222a482fb", "customerName": "Ivan Barrera", "internalName": "Jaden Dankevy", "customerEmail": "ivan.barrera@novartis.com", "internalEmail": "jaden.dankevy@biorender.com", "speakerId": "766346542485550655", "sizeMentions": [], "contextBefore": "...nder from them.\n[Speaker 766346542485550655]: So, I mean, I'm assuming that they had access to it at some point, if not, you know, currently available.\n[Speaker 979644929967199604]: Yeah.\n[Speaker 979644929967199604]: Some people used to have like a lot of people used to have access in the past, and then Novartis got a little bit stricter with licensing before security review was done.\n[Speaker 979644929967199604]: And now that the security review is done, they've kind of opened up access to apply for the licenses again, which is great.\n[Speaker 979644929967199604]: So I guess my question for you would be like what group are you a part of?\n[Speaker 979644929967199604]: Oh, okay.\n[Speaker 979644929967199604]: Yeah.\n[Speaker 766346542485550655]: So, I mean, right now, I'm in CVM which is the cardiovascular and metabolic disease group.\n[Speaker 766346542485550655]: Yeah.\n[Speaker 766346542485550655]: Okay.\n[Speaker 766346542485550655]: I'm over in Cambridge.\n[Speaker 766346542485550655]: ", "contextAfter": "\n[Speaker 979644929967199604]: Yeah.\n[Speaker 979644929967199604]: Okay.\n[Speaker 979644929967199604]: That's good to know.\n[Speaker 979644929967199604]: I think we definitely have had some users from CVM.\n[Speaker 979644929967199604]: So I'd be curious to see if they still have access.\n[Speaker 979644929967199604]: The reason I ask, well, actually, I wanted to ask as well.\n[Speaker 979644929967199604]: What are you hoping to use BioRender for?\n[Speaker 979644929967199604]: Is it primarily internal presentations?\n[Speaker 979644929967199604]: Because that's what we've heard most people are making use of before.\n[Speaker 979644929967199604]: Yeah, yeah.\n[Speaker 766346542485550655]: It really would just be for internal presentations Right now.\n[Speaker 766346542485550655]: I'm not working on any type of manuscript or.\n[Speaker 979644929967199604]: Publications or anything.\n[Speaker 979644929967199604]: No.\n[Speaker 979644929967199604]: I think that's why most people are getting access A...", "callTitle": "BioRender & Novartis - Intro Call"}, {"quote": "So we have BR, it's biomedical research", "date": "2025-01-10", "gongUrl": "https://app.gong.io/call?id=5d15653f349d996cc5b49ac289c82e331df8445167f7a73e534e046c1bf4f1bc", "callId": "2025-01-10_5d15653f349d", "customerName": "Samu Melkko", "internalName": "Ross Proudfoot", "customerEmail": "samu.melkko@novartis.com", "internalEmail": "ross@biorender.com", "speakerId": "233530352534476423", "sizeMentions": [], "contextBefore": "...e if I remember correctly, and I thought it's really impressive And I know some colleagues have used BioRender.\n[Speaker 233530352534476423]: Meanwhile, I think back in the time there was somebody from oncology and us who were both interested, but kind of there was no traction at the time from outside to move it further.\n[Speaker 233530352534476423]: And now I'm actually not updated at all what the situation is.\n[Speaker 233530352534476423]: If, you know, if, you know, Novartis, some departments have a license and how it is exactly.\n[Speaker 233530352534476423]: I just know one colleague who's using it but I don't know how and what the license situation is right now.\n[Speaker 8434859750879709595]: Yeah.\n[Speaker 8434859750879709595]: And you mentioned like oncology being interested, Are you from an adjacent group or which sort of?\n[Speaker 233530352534476423]: I'm in immunology.\n[Speaker 233530352534476423]: So we have different disease areas in research.\n[Speaker 233530352534476423]: ", "contextAfter": ", and there are different units within research, like the different disease areas like, you know, oncology, immunology, neuroscience, and so on cardiovascular, They are different.\n[Speaker 233530352534476423]: It's the locations are mostly in Basel in Switzerland and in Cambridge, you know, Massachusetts.\n[Speaker 233530352534476423]: Yeah.\n[Speaker 233530352534476423]: And then there's some other sites, GNF in San Diego, and so on.\n[Speaker 233530352534476423]: And then there are platforms like Biologics, Lomel, Kuwait, Screening things like this And it's you know, we of course, collaborate in project teams and everything.\n[Speaker 233530352534476423]: But each of these units have their own kind of oncology etymology head and so on.\n[Speaker 8434859750879709595]: Yeah.\n[Speaker 8434859750879709595]: So we've like I guess to give you a bit of information on how it's getting set up is there are so many different sort of small groups either purchasing or even individuals that would just ...", "callTitle": "BioRender & Novartis - Intro Call"}, {"quote": "Are you a part of biomedical research then like the BR group?", "date": "2024-10-04", "gongUrl": "https://app.gong.io/call?id=d3321342d25a6a35e8ba18d106cb31dd11f5ec75aeed1b5eb4c9080fe232f6c0", "callId": "2024-10-04_d3321342d25a", "customerName": "Shwetha Iyer", "internalName": "Jaden Dankevy; Ross Proudfoot", "customerEmail": "shwetha.iyer@novartis.com", "internalEmail": "jaden.dankevy@biorender.com; ross@biorender.com", "speakerId": "5430927708339458581", "sizeMentions": [], "contextBefore": "...il saying that my account has been on hold or something like that.\n[Speaker 2765675683771798832]: So, I have no idea what's happening.\n[Speaker 5430927708339458581]: Yeah, we can definitely start and sort of update you there as well.\n[Speaker 5430927708339458581]: So, just to give you a bit of information in my role, I basically help all different areas of Novartis.\n[Speaker 5430927708339458581]: So, covering the whole organization with any BioRender licensing.\n[Speaker 5430927708339458581]: As well with that too, like Jaden and I do support like anybody that needs training.\n[Speaker 5430927708339458581]: Or sort of any updates on the product or uses of the product.\n[Speaker 5430927708339458581]: So, we do support with like webinars and things like that as well.\n[Speaker 5430927708339458581]: There is a central license available at Novartis.\n[Speaker 5430927708339458581]: So, that's probably what you had heard about where that email was internal or what.\n[Speaker 5430927708339458581]: ", "contextAfter": "\n[Speaker 5430927708339458581]: Yes.\n[Speaker 2974905774264093123]: So, it's pretty interesting.\n[Speaker 2974905774264093123]: They've got it.\n[Speaker 2974905774264093123]: setup where if you're in VR, you're.\n[Speaker 5430927708339458581]: able to request directly through the App Store for BioRender licensing, but we do have BioRender licensing available for those outside of VR as well within Novartis.\n[Speaker 5430927708339458581]: So, currently, VR holds like its own sort of separate central license across a number of different departments within the group, and so you're able to request access that way as well.\n[Speaker 5430927708339458581]: I am from like an account flagging site, like Jaden just updated me.\n[Speaker 5430927708339458581]: I guess our support team sent a ping through that you're on an academic license, which is just our, like it's available for schools.\n[Speaker 5430927708339458581]: It can't be used for like industry papers or industry commercial uses, and so Nov...", "callTitle": "BioRender & Novartis - Intro Call"}, {"quote": "I think primarily it was biomedical research but we do have like a TRD license as well now", "date": "2024-09-06", "gongUrl": "https://app.gong.io/call?id=169896fe10d3c8d7ef75c09e16265eb99e34ccc5d53a6ea03ba7c235f1c2ea02", "callId": "2024-09-06_169896fe10d3", "customerName": "Adam Tomaszewski; Adam Tomaszewski; Linda Chin", "internalName": "Ross Proudfoot", "customerEmail": "adam.tomaszewski@novartis.com; adam.tomaszewski@novartis.com; linda.chin@novartis.com; oswaldo.chavez_gonzalez@novartis.com", "internalEmail": "ross@biorender.com", "speakerId": "4790105840873293174", "sizeMentions": [], "contextBefore": "...53763]: Yes, I'm meeting him.\n[Speaker 4235260981558453763]: I am meeting him next week to discuss.\n[Speaker 4235260981558453763]: I'm not sure what's going on there.\n[Speaker 4235260981558453763]: I just, he sent me an invite for, let me see, when did he send it to me?\n[Speaker 4235260981558453763]: BioRender contract for Wednesday, so I hope that we have that, but he didn't add any details.\n[Speaker 4235260981558453763]: At this time to discuss the business needs for this project that you can send this request to the right people in the business so we can solve legal team doubts.\n[Speaker 4235260981558453763]: Okay, I need to check this first.\n[Speaker 4790105840873293174]: I'm guessing it hasn't really been like top of pile at all kind of through the summer.\n[Speaker 4790105840873293174]: I know like I've reached out to him a couple times and one of his concerns was kind of figuring out like what what's the price and like how big sort of the download going to be across Novartis and ", "contextAfter": ", a small one, and I know they're interested Yeah.\n[Speaker 4235260981558453763]: You can always get started with him at something between 100 and 150,000.\n[Speaker 4235260981558453763]: This will be short term, right?\n[Speaker 4235260981558453763]: With growing potential.\n[Speaker 4235260981558453763]: But I will tell him this because the 100 K threshold is what the procurement needs to be involved.\n[Speaker 4235260981558453763]: And we can't go too high.\n[Speaker 4235260981558453763]: So this is why something between 100 and 150 K, I will tell him.\n[Speaker 4235260981558453763]: But I think he also wants to discuss some of the red lines.\n[Speaker 4235260981558453763]: I'll just double check.\n[Speaker 4235260981558453763]: Let's see.\n[Speaker 4235260981558453763]: Yep.\n[Speaker 7924696289706526772]: Okay, no, that makes sense.\n[Speaker 7924696289706526772]: And I think, yeah, like,\n[Speaker 4790105840873293174]: in terms of if he has any sort of questions regarding the product, like, ...", "callTitle": "New Novartis//BioRender Weekly Cadence"}, {"quote": "It's biomedical research or, and, or within the immunology department", "date": "2023-10-06", "gongUrl": "https://app.gong.io/call?id=c6587a1bc0b6fb42e5da665c0b932422bfb43fe9a60db14c14f4882774b74ed5", "callId": "2023-10-06_c6587a1bc0b6", "customerName": "Adam; Adam; Petra Simic", "internalName": "Ross Proudfoot; Walid Habboub", "customerEmail": "adam.tomaszewski@novartis.com; adam.tomaszewski@novartis.com; petra.simic@novartis.com", "internalEmail": "ross@biorender.com; walid@biorender.com", "speakerId": "8550764551772876224", "sizeMentions": [], "contextBefore": "...2]: Good to see you.\n[Speaker 8550764551772876224]: Right.\n[Speaker 8550764551772876224]: And Patrick.\n[Speaker 1388177930282429252]: Great meeting you for the first time as well.\n[Speaker 1388177930282429252]: I believe you're coming from the immunology side, correct?\n[Speaker 1388177930282429252]: With?\n[Speaker 8550764551772876224]: Yes, I'm the head of operations and immunology.\n[Speaker 8550764551772876224]: So I'm basically responsible for the resource planning, spend et cetera.\n[Speaker 8550764551772876224]: And that's why I also got involved in the discussion about licenses, number of licenses and costs and thanks, for joining, and I think we were able to clarify a few things in, before this meeting thanks to Adam, and his colleague.\n[Speaker 8550764551772876224]: There was a bit of a confusion about what kind of licenses we are talking about, who has licenses within lever.\n[Speaker 8550764551772876224]: And, I shouldn't say never anymore, right?\n[Speaker 8550764551772876224]: ", "contextAfter": " because there seem to be separate streams at the same time.\n[Speaker 8550764551772876224]: People being in touch with you directly Ross others consolidating internally, Adam, but, I think we all talked about the same thing, in the end and we have an overview about how many paid licenses we currently have in immunology and how many people are using the freely available license.\n[Speaker 8550764551772876224]: This, thanks Adam for compiling that.\n[Speaker 8550764551772876224]: That was super helpful.\n[Speaker 8550764551772876224]: I just would like to understand a little bit first of all, what is the difference between the two.\n[Speaker 8550764551772876224]: I mean, obviously one is paid.\n[Speaker 8550764551772876224]: The other one is not, but what are the limitations with the non paid ones?\n[Speaker 8550764551772876224]: And I understood also that we would prefer to go, with the full license because I want to understand what are the implications also if I make a bit more of a noise ab...", "callTitle": "Novartis Immunology // BioRender"}], "confidence": "medium", "status": "auto_matched"}, "children": [{"id": "oncology-research", "name": "Oncology Research", "type": "therapeutic_area", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "solid-tumors", "name": "Solid Tumors", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "hematologic-malignancies", "name": "Hematologic Malignancies", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "cardiovascular-renal-metabolic", "name": "Cardiovascular, Renal & Metabolic Diseases", "type": "therapeutic_area", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "heart-failure", "name": "Heart Failure", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "cardiometabolic", "name": "Cardiometabolic", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "immunology-research", "name": "Immunology", "type": "therapeutic_area", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 10, "teamSizes": [], "sizeMentions": [], "snippets": [{"quote": "Biorender is being used at various departments within novartis including oncology, immunology", "date": "2025-12-15", "gongUrl": "https://app.gong.io/call?id=af4b5d9111d778c95d0f4952a90fdfcfb6da57621b0ca4f70be43cc412c3d8da", "callId": "2025-12-15_af4b5d9111d7", "customerName": "Oliver Pohl", "internalName": "Sofiya Medvezhonkova", "customerEmail": "oliver.pohl@novartis.com", "internalEmail": "sofiya.m@biorender.com", "speakerId": "8860790880597591384", "sizeMentions": [], "contextBefore": "[Speaker 6058437699674532906]: hello?\n[Speaker 8860790880597591384]: Hi, am I speaking to Oliver at novartis?\n[Speaker 6058437699674532906]: Hi.\n[Speaker 6058437699674532906]: Yeah, that's me, Oliver.\n[Speaker 6058437699674532906]: Hi.\n[Speaker 8860790880597591384]: Hi, Oliver.\n[Speaker 8860790880597591384]: This is Sofiya, giving you a call from biorender.\n[Speaker 8860790880597591384]: I'm just following up on an email I sent not too long ago.\n[Speaker 8860790880597591384]: I was wondering if right now you had a moment to chat?\n[Speaker 6058437699674532906]: Yes, but what is it about?\n[Speaker 8860790880597591384]: Yeah, absolutely to provide some more context, we're one of the vendor partners at novartis for biorender.\n[Speaker 8860790880597591384]: Are you familiar with what biorender is?\n[Speaker 6058437699674532906]: I know, please explain.\n[Speaker 8860790880597591384]: Yes, I can definitely explain.\n[Speaker 8860790880597591384]: ", "contextAfter": ", there.\n[Speaker 8860790880597591384]: Yes.\n[Speaker 6058437699674532906]: Can you spell it?\n[Speaker 6058437699674532906]: Bio?\n[Speaker 6058437699674532906]: Pardon me?\n[Speaker 6058437699674532906]: Can you spell it?\n[Speaker 6058437699674532906]: Bio?\n[Speaker 8860790880597591384]: Biorender RENDER.\n[Speaker 6058437699674532906]: Okay.\n[Speaker 8860790880597591384]: Yeah.\n[Speaker 8860790880597591384]: And we're being used to help scientists and leaders, kind of communicate their research through scientific illustrations.\n[Speaker 8860790880597591384]: So, scientists will typically use us to create their scientific figures for their presentations or publications.\n[Speaker 8860790880597591384]: Does that ring a bell at all?\n[Speaker 6058437699674532906]: Well, I usually do not provide any slide decks or something like that.\n[Speaker 6058437699674532906]: I mean, medical information.\n[Speaker 6058437699674532906]: I do answer questions but I do not prepare material.\n[Speaker 8860790...", "callTitle": "Call with Novartis - Oliver Pohl"}, {"quote": "So oncology, their immunology just come up top of mind for me", "date": "2025-12-12", "gongUrl": "https://app.gong.io/call?id=76ea16c091b3b934aa24e7c1c700937bdd70675692b817ac96a17e5cb6f61fb6", "callId": "2025-12-12_76ea16c091b3", "customerName": "Julius Decano", "internalName": "Sofiya Medvezhonkova", "customerEmail": "julius.decano@novartis.com", "internalEmail": "sofiya.m@biorender.com", "speakerId": "3200669453604377621", "sizeMentions": [], "contextBefore": "...hey just joined actually this October.\n[Speaker 3200669453604377621]: Wonderful.\n[Speaker 3200669453604377621]: Yeah.\n[Speaker 3200669453604377621]: First of all, in that case, what I can do is I can definitely send you over a premium trial for 30 days for which.\n[Speaker 7482502800940294767]: Is perfect.\n[Speaker 7482502800940294767]: Perfect.\n[Speaker 3200669453604377621]: Enough time?\n[Speaker 3200669453604377621]: Yeah, for your presentation and you'll be able to have all the premium functionality.\n[Speaker 3200669453604377621]: So since you last used it two years ago, quite a few things have changed yeah.\n[Speaker 7482502800940294767]: We.\n[Speaker 3200669453604377621]: set up demonstrations for different teams to showcase all the functionality and kind of like gauge interest.\n[Speaker 3200669453604377621]: We're actually partnered already, you know, with novartis and we have a couple of departments that are already like using us for broader access.\n[Speaker 3200669453604377621]: ", "contextAfter": ".\n[Speaker 3200669453604377621]: And I have seen interest to grow within CBM as well.\n[Speaker 3200669453604377621]: Was that the department that you're a part of?\n[Speaker 3200669453604377621]: Yeah.\n[Speaker 7482502800940294767]: Yeah.\n[Speaker 7482502800940294767]: The CBM, yeah.\n[Speaker 7482502800940294767]: Right now, there's like just two of us that has interest, I guess, but we'll see the thing is I do echocardiography that's why a lot of my presentations will have like animations and illustrations.\n[Speaker 7482502800940294767]: So it'll be very helpful if I have like a good, you know\u2026 source of like to make my diagrams and all that.\n[Speaker 7482502800940294767]: So, yeah.\n[Speaker 3200669453604377621]: Yeah, precisely.\n[Speaker 3200669453604377621]: And you mentioned requesting, you know, you spoke speaking to your lab manager about that.\n[Speaker 3200669453604377621]: Is that the other person that was using it or no?\n[Speaker 7482502800940294767]: No, another associate but ...", "callTitle": "BioRender & Novartis - Intro Call"}, {"quote": "So neurosciences, immunology, cardiovascular metabolism, etc", "date": "2025-12-04", "gongUrl": "https://app.gong.io/call?id=9b50b1639ecf5aaed5db8d27bfc49d4f79618c5553ad975ba0cbb14c51ecdaf5", "callId": "2025-12-04_9b50b1639ecf", "customerName": "Albert Misko", "internalName": "Ross Proudfoot; Sofiya Medvezhonkova", "customerEmail": "albert.misko@novartis.com", "internalEmail": "ross@biorender.com; sofiya.m@biorender.com", "speakerId": "540529526687666601", "sizeMentions": [], "contextBefore": "...ational medicine.\n[Speaker 7027995544158346041]: Is that correct?\n[Speaker 7027995544158346041]: Yeah?\n[Speaker 540529526687666601]: Correct.\n[Speaker 540529526687666601]: And neurosciences within translational medicine?\n[Speaker 7027995544158346041]: Okay.\n[Speaker 7027995544158346041]: And, is that separate from like neurosciences as a discovery?\n[Speaker 7027995544158346041]: Okay.\n[Speaker 7027995544158346041]: So TM is sort of its own instance, is it, so to be like I'm guessing this is how it is, but it would be great to have some clarity.\n[Speaker 7027995544158346041]: Is it like every TM will sort of have an associated group with some of those discovery departments?\n[Speaker 7027995544158346041]: Like would there also be sort of a translational medicine, oncology or rare disease?\n[Speaker 7027995544158346041]: Okay?\n[Speaker 7027995544158346041]: The way it's.\n[Speaker 540529526687666601]: broken down is on the discovery side, it's by disease area.\n[Speaker 540529526687666601]: ", "contextAfter": ", and they work like big labs, right?\n[Speaker 540529526687666601]: It's like there's one head of all of neuroscience.\n[Speaker 540529526687666601]: And then under him there's neurodegeneration, neuroinflammation, and neuromuscular, and then there's labs under those heads that all work.\n[Speaker 7027995544158346041]: Towards that, and.\n[Speaker 540529526687666601]: Then in translational medicine, it's two divisions.\n[Speaker 540529526687666601]: One division is by sort of what you do.\n[Speaker 540529526687666601]: So I sit in tdmp which is target discovery and profiling.\n[Speaker 540529526687666601]: It's basically the medical leads that's really what we are.\n[Speaker 540529526687666601]: We're the medical leads and but then there's biomarkers, there's pkpf, pkpd, there is PCS, which is preclinical safety.\n[Speaker 540529526687666601]: There's statistics.\n[Speaker 540529526687666601]: There's you know, regulatory all of that.\n[Speaker 540529526687666601]: And then those columns are div...", "callTitle": "BioRender & Novartis - Intro Call"}, {"quote": "Yeah, I'm from immunology", "date": "2025-07-04", "gongUrl": "https://app.gong.io/call?id=8e4009585731cfafa3e9eafd1b9b09f5ee3d12a80df4ee555644aa6d7d7effe6", "callId": "2025-07-04_8e4009585731", "customerName": "Zuni Bassi", "internalName": "Ross Proudfoot", "customerEmail": "zuni.bassi@novartis.com", "internalEmail": "ross@biorender.com", "speakerId": "3626252761295043604", "sizeMentions": [], "contextBefore": "...ort conversation with you, but I guess I'll introduce myself and really just let you kind of lead and, you know, get what you'd like out of the meeting.\n[Speaker 2355354121190058325]: I know we've only set up 15 minutes.\n[Speaker 2355354121190058325]: So, I'm the account executive here at biorender.\n[Speaker 2355354121190058325]: So I support like all of biorender licensing across novartis.\n[Speaker 2355354121190058325]: I've been supporting lots of different groups within VR, both through like a central chargeback sort of license where individuals have been able to get access, but now as well with individual department access as well.\n[Speaker 2355354121190058325]: So, I'm kind of up to speed on what's going on I guess across the company in terms of like who's using biorender, how it's sort of being leveraged, which is hopefully great to share some information.\n[Speaker 2355354121190058325]: And I guess like it looks like you're from immunology as well.\n[Speaker 3626252761295043604]: ", "contextAfter": ", I know of colleagues that are using it.\n[Speaker 3626252761295043604]: I have never used it before.\n[Speaker 3626252761295043604]: I've seen figures generated with it, but I haven't used it before but, and I know some time ago, there was some colleagues.\n[Speaker 3626252761295043604]: I don't know if joschka, wilsman\u2026 and grigory, rydzak?\n[Speaker 2355354121190058325]: Yeah, yeah.\n[Speaker 3626252761295043604]: Who mentioned I can't remember, but they were asking like, is there someone else interested in using biorender?\n[Speaker 3626252761295043604]: Because we could have kind of a license that could be used by several people.\n[Speaker 3626252761295043604]: I don't I remember asking them asking.\n[Speaker 3626252761295043604]: I remember them asking if someone would be interested in using it.\n[Speaker 3626252761295043604]: I said that I would, but then nothing happened and it's I think if I had it, I would use it.\n[Speaker 3626252761295043604]: It's just not clear to me how I get a l...", "callTitle": "BioRender & Novartis - Intro Call : Zuni Bassi"}, {"quote": "I know immunology and biologics kind of got flagged to us", "date": "2025-04-16", "gongUrl": "https://app.gong.io/call?id=0ed32b9f3917ab20a34cd65d8d0318286c374126df243c1396c80ca24384a4fb", "callId": "2025-04-16_0ed32b9f3917", "customerName": "Adam Tomaszewski; Adam Tomaszewski; Linda Chin", "internalName": "Ross Proudfoot; Tim Fung", "customerEmail": "adam.tomaszewski@novartis.com; adam.tomaszewski@novartis.com; linda.chin@novartis.com", "internalEmail": "ross@biorender.com; tim@biorender.com", "speakerId": "8312379094350391382", "sizeMentions": [], "contextBefore": "...2379094350391382]: I would probably say makes the most sense to move over to a defined group and remain separate from the name.\n[Speaker 8312379094350391382]: I.\n[Speaker 2567351405035696877]: Think, I think oncology is much bigger.\n[Speaker 2567351405035696877]: They're.\n[Speaker 8312379094350391382]: they're also another one that's got quite a bit of licensing, but dare, I think it's at 33, right?\n[Speaker 8312379094350391382]: Tim.\n[Speaker 8742906523335327100]: I think so.\n[Speaker 8742906523335327100]: It's like 33 or 35 people.\n[Speaker 8742906523335327100]: Yeah?\n[Speaker 8742906523335327100]: Based.\n[Speaker 8312379094350391382]: On their size, that's, a high user rate maybe even compared to oncology, but oncology would get another one with, I think they're close to 54 or 55 looking at in the spreadsheet that she shared.\n[Speaker 8312379094350391382]: So those would be two where I think it's worth definitely having a discussion and then other areas where there's interest like, ", "contextAfter": " so you can explore with them as well.\n[Speaker 8312379094350391382]: Okay?\n[Speaker 1821801272283730809]: Cool.\n[Speaker 1821801272283730809]: Then.\n[Speaker 2567351405035696877]: This was a quick one.\n[Speaker 1821801272283730809]: Yeah, Ross, so I just sent back the email about Adam's question, how you were missing some people.\n[Speaker 8312379094350391382]: They would have been the pending users.\n[Speaker 1821801272283730809]: Not the pending ones but the ones below, there were four people listed there, that is on our portal, but not in your list.\n[Speaker 1821801272283730809]: Your full list.\n[Speaker 1821801272283730809]: OK, yeah, definitely.\n[Speaker 8312379094350391382]: The admin panel is going to be their source of truth.\n[Speaker 8312379094350391382]: Sometimes their overall data with like free users and paid users can be a little bit wonky.\n[Speaker 8312379094350391382]: Just, the data source there isn't always the cleanest.\n[Speaker 8312379094350391382]: So I'll keep an e...", "callTitle": "BioRender - Novartis Central BR Renewal"}, {"quote": "Lab had it within Immunology, but I think she's part of PCS.", "date": "2025-01-28", "gongUrl": "https://app.gong.io/call?id=590515e45affc7a044cf18406ab5caa7c68908aaad4ce2564dc7078e4f417f64", "callId": "2025-01-28_590515e45aff", "customerName": "Battuja Dugershaw-Kurzer; Battuja Dugershaw-Kurzer", "internalName": "Jaden Dankevy", "customerEmail": "battuja.dugershaw-kurzer@novartis.com; battuja.dugershaw-kurzer@novartis.com", "internalEmail": "jaden.dankevy@biorender.com", "speakerId": "4709327903517203486", "sizeMentions": [], "contextBefore": "...acted somebody with the first name of Michelle.\n[Speaker 2192309733355281827]: I haven't talked to Hannah Morgan yet.\n[Speaker 2192309733355281827]: Do you know where she's based?\n[Speaker 2192309733355281827]: If she's based in the U.\n[Speaker 2192309733355281827]: S, or in Basel?\n[Speaker 4709327903517203486]: Hmm.\n[Speaker 4709327903517203486]: All good.\n[Speaker 4709327903517203486]: Let me double check for you.\n[Speaker 2192309733355281827]: Or maybe I'll let you finish your thought first or your sentence first because I guess you were trying to go somewhere with mentioning Hannah Morgan.\n[Speaker 4709327903517203486]: Yeah, no, I did.\n[Speaker 4709327903517203486]: We were just curious if you guys had connected on like doing say like a demonstration or something for the group or a trial or something like that or at BioRender.\n[Speaker 4709327903517203486]: But I guess not, She is, she's in Basel.\n[Speaker 4709327903517203486]: She's in Basel.\n[Speaker 4709327903517203486]: Yeah, ", "contextAfter": "\n[Speaker 4709327903517203486]: Would that make sense?\n[Speaker 2192309733355281827]: No, no, No, I haven't She is, Which is good.\n[Speaker 2192309733355281827]: That would make sense because not only is PCS scattered around the globe, we also have different role and mind functions, which means you will have subject matter expertise from different therapeutic areas like immunology or oncology and stuff like that.\n[Speaker 4709327903517203486]: Yes.\n[Speaker 4709327903517203486]: Okay.\n[Speaker 4709327903517203486]: That makes sense.\n[Speaker 4709327903517203486]: Now.\n[Speaker 4709327903517203486]: Did you, Adam, I believe is Adam, part of procurement?\n[Speaker 4709327903517203486]: Is that who you reached out to?\n[Speaker 2192309733355281827]: So, I mentioned Adam.\n[Speaker 2192309733355281827]: So the thing is there's someone who is looking into.\n[Speaker 2192309733355281827]: So what did you say?\n[Speaker 2192309733355281827]: Adam, Who?\n[Speaker 4709327903517203486]: I'm just curio...", "callTitle": "Call with Novartis - Battuja Dugershaw-kurzer"}, {"quote": "I'm in immunology", "date": "2025-01-10", "gongUrl": "https://app.gong.io/call?id=5d15653f349d996cc5b49ac289c82e331df8445167f7a73e534e046c1bf4f1bc", "callId": "2025-01-10_5d15653f349d", "customerName": "Samu Melkko", "internalName": "Ross Proudfoot", "customerEmail": "samu.melkko@novartis.com", "internalEmail": "ross@biorender.com", "speakerId": "233530352534476423", "sizeMentions": [], "contextBefore": "...re was kind of a promotion email or something and I looked at a video or some of the material and there was a talk at some stage if I remember correctly, and I thought it's really impressive And I know some colleagues have used BioRender.\n[Speaker 233530352534476423]: Meanwhile, I think back in the time there was somebody from oncology and us who were both interested, but kind of there was no traction at the time from outside to move it further.\n[Speaker 233530352534476423]: And now I'm actually not updated at all what the situation is.\n[Speaker 233530352534476423]: If, you know, if, you know, Novartis, some departments have a license and how it is exactly.\n[Speaker 233530352534476423]: I just know one colleague who's using it but I don't know how and what the license situation is right now.\n[Speaker 8434859750879709595]: Yeah.\n[Speaker 8434859750879709595]: And you mentioned like oncology being interested, Are you from an adjacent group or which sort of?\n[Speaker 233530352534476423]: ", "contextAfter": ".\n[Speaker 233530352534476423]: So we have different disease areas in research.\n[Speaker 233530352534476423]: So we have BR, it's biomedical research, and there are different units within research, like the different disease areas like, you know, oncology, immunology, neuroscience, and so on cardiovascular, They are different.\n[Speaker 233530352534476423]: It's the locations are mostly in Basel in Switzerland and in Cambridge, you know, Massachusetts.\n[Speaker 233530352534476423]: Yeah.\n[Speaker 233530352534476423]: And then there's some other sites, GNF in San Diego, and so on.\n[Speaker 233530352534476423]: And then there are platforms like Biologics, Lomel, Kuwait, Screening things like this And it's you know, we of course, collaborate in project teams and everything.\n[Speaker 233530352534476423]: But each of these units have their own kind of oncology etymology head and so on.\n[Speaker 8434859750879709595]: Yeah.\n[Speaker 8434859750879709595]: So we've like I guess to give you a bit...", "callTitle": "BioRender & Novartis - Intro Call"}, {"quote": "I'm also head of operations for immunology, and we are located in base", "date": "2024-03-01", "gongUrl": "https://app.gong.io/call?id=7b31b87ac1bd97c480914d2a3847bec6652478931e5b2f06276fa50103a7fb6e", "callId": "2024-03-01_7b31b87ac1bd", "customerName": "Adam; Carlos-2 Lopez; Linda Chin; Marion Wiesmann; Petra Simic; Stefan Melly", "internalName": "Ross Proudfoot; Walid Habboub", "customerEmail": "adam.tomaszewski@novartis.com; carlos-2.lopez_ext@novartis.com; linda.chin@novartis.com; marion.wiesmann@novartis.com; petra.simic@novartis.com; stefan.melly@novartis.com; sandra.calles@novartis.com", "internalEmail": "ross@biorender.com; walid@biorender.com", "speakerId": "6182642638753237594", "sizeMentions": [], "contextBefore": "...: So, you know, I'm a science background as well.\n[Speaker 8450172025579479033]: I do have an MSC, so I speak a little bit of the language, but I'm a bit removed from that side but happy to kind of take you through any sort of questions that you have on the platform itself.\n[Speaker 8450172025579479033]: I know Angela if you wanted to kick things off and.\n[Speaker 6550203676745257136]: Okay.\n[Speaker 6550203676745257136]: Yeah.\n[Speaker 6550203676745257136]: So my name is Angela.\n[Speaker 6550203676745257136]: I'm the head of operations like most of us, our first scientific department within the BR division, the biometric research.\n[Speaker 6550203676745257136]: I'm taking care of the biologic department which is, in the us and in Switzerland.\n[Speaker 6550203676745257136]: Perfect.\n[Speaker 6550203676745257136]: Petra.\n[Speaker 6550203676745257136]: I just can't do on the Petra.\n[Speaker 6550203676745257136]: Yeah, I do a hand off name after.\n[Speaker 6182642638753237594]: So, Petra, ", "contextAfter": " and I hand over to Marion\u2026 muted Marion.\n[Speaker 5598099072264006698]: Can't hear you\u2026 maybe the wrong setting, the wrong device setting the wrong Mike.\n[Speaker 7692361625660778700]: Can, can you hear?\n[Speaker 5598099072264006698]: Me now?\n[Speaker 5598099072264006698]: Yes?\n[Speaker 7692361625660778700]: I'm struggling headset off and on.\n[Speaker 7692361625660778700]: So Maria head of oncology, I'm based in base, but we have groups in as cambridge and San Diego, and on the call here are also joseppe and Sonia for each of the sites.\n[Speaker 7692361625660778700]: I don't know if wants to go next.\n[Speaker 5598099072264006698]: Maybe Marjorie.\n[Speaker 6630647164737669272]: Hi, I'm Margery Iris and I'm in cambridge.\n[Speaker 6630647164737669272]: I am the head of operations, neuroscience, and we also have laboratories in Basel, cambridge and San Diego.\n[Speaker 5598099072264006698]: I think Giuseppe maybe can go next.\n[Speaker 5598099072264006698]: I want to.\n[Speaker 6550203676745...", "callTitle": "Novartis // BioRender Weekly Cadence"}, {"quote": "However, my coworkers are working on immunology\u2026 oncology and, cardio, right?", "date": "2024-02-08", "gongUrl": "https://app.gong.io/call?id=af0e68dc4453e730c5fed1e64dcbea09d570f40970722a0c7508ee2cf5653141", "callId": "2024-02-08_af0e68dc4453", "customerName": "Elsie Gonzalez; Elsie Gonzalez", "internalName": "Ross Proudfoot", "customerEmail": "elsie.gonz@novartis.com; elsie.gonz@novartis.com", "internalEmail": "ross@biorender.com", "speakerId": "8052422846018822405", "sizeMentions": [], "contextBefore": "...hem the whole context and it's been a very effective strategy.\n[Speaker 8052422846018822405]: It seems, yeah.\n[Speaker 8052422846018822405]: And all of these doctors have been very receptive to receiving this type of education, this type of updating of the literature of the evidence of all of these things.\n[Speaker 8052422846018822405]: And it has resulted in Novartis products on like their sales implement, yeah, their sales increasing and their sales just shooting through the roof.\n[Speaker 8052422846018822405]: Because we are a competitive.\n[Speaker 8052422846018822405]: We do have competitive molecules on our portfolio.\n[Speaker 8052422846018822405]: And so the science speaks for itself.\n[Speaker 8052422846018822405]: That is kind of the strategy that we're implementing right now.\n[Speaker 8052422846018822405]: And so I've recently joined this team in December and I've been assigned the therapeutic areas of chematology and\u2026 chemotology, and neurology.\n[Speaker 8052422846018822405]: ", "contextAfter": "\n[Speaker 1561964586350796361]: Yeah.\n[Speaker 8052422846018822405]: Yeah.\n[Speaker 8052422846018822405]: So what we're doing right now is we a, well, the, it started with cardio but the therapeutic, it went so well that the therapeutic areas are reaching out to us and saying, hey, we want you to start educating our doctors and subtly mentioning auto molecule because it looks like it's doing really well for the company.\n[Speaker 8052422846018822405]: So, yeah, I'm right now working on a presentation that I was supposed to go to the university of one, to do this is very, not related to my therapeutic areas but it was on safety and efficacy of hyperv, different hypertensiv agents.\n[Speaker 8052422846018822405]: So three E medications at not had a couple of years ago.\n[Speaker 8052422846018822405]: It's a little outdated but they asked me to do it.\n[Speaker 8052422846018822405]: So I'm doing it right?\n[Speaker 8052422846018822405]: And I've U, I was part of the research team at the jam la...", "callTitle": "BioRender & Novartis - Intro Call"}, {"quote": "Yes, I'm the head of operations and immunology.", "date": "2023-10-06", "gongUrl": "https://app.gong.io/call?id=c6587a1bc0b6fb42e5da665c0b932422bfb43fe9a60db14c14f4882774b74ed5", "callId": "2023-10-06_c6587a1bc0b6", "customerName": "Adam; Adam; Petra Simic", "internalName": "Ross Proudfoot; Walid Habboub", "customerEmail": "adam.tomaszewski@novartis.com; adam.tomaszewski@novartis.com; petra.simic@novartis.com", "internalEmail": "ross@biorender.com; walid@biorender.com", "speakerId": "8550764551772876224", "sizeMentions": [], "contextBefore": "... always have to do visor browser because we cannot download the Zoom app.\n[Speaker 8550764551772876224]: So it's a bit complicated, but here we are sorry for the delay.\n[Speaker 5714734027452388150]: We can try teams.\n[Speaker 1388177930282429252]: Yeah, I know you guys use teams quite a bit.\n[Speaker 1388177930282429252]: We should, we should get teams accounts so that we're not because we're browser through the teams.\n[Speaker 1388177930282429252]: So, but\u2026\n[Speaker 5714734027452388150]: Hi.\n[Speaker 1388177930282429252]: Glad we could get a hold of you guys though.\n[Speaker 7533577058510426469]: I was good to see you again.\n[Speaker 1388177930282429252]: Good to see you.\n[Speaker 8550764551772876224]: Right.\n[Speaker 8550764551772876224]: And Patrick.\n[Speaker 1388177930282429252]: Great meeting you for the first time as well.\n[Speaker 1388177930282429252]: I believe you're coming from the immunology side, correct?\n[Speaker 1388177930282429252]: With?\n[Speaker 8550764551772876224]: ", "contextAfter": "\n[Speaker 8550764551772876224]: So I'm basically responsible for the resource planning, spend et cetera.\n[Speaker 8550764551772876224]: And that's why I also got involved in the discussion about licenses, number of licenses and costs and thanks, for joining, and I think we were able to clarify a few things in, before this meeting thanks to Adam, and his colleague.\n[Speaker 8550764551772876224]: There was a bit of a confusion about what kind of licenses we are talking about, who has licenses within lever.\n[Speaker 8550764551772876224]: And, I shouldn't say never anymore, right?\n[Speaker 8550764551772876224]: It's biomedical research or, and, or within the immunology department because there seem to be separate streams at the same time.\n[Speaker 8550764551772876224]: People being in touch with you directly Ross others consolidating internally, Adam, but, I think we all talked about the same thing, in the end and we have an overview about how many paid licenses we currently have in immuno...", "callTitle": "Novartis Immunology // BioRender"}], "confidence": "medium", "status": "auto_matched"}, "children": [{"id": "autoimmune-diseases", "name": "Autoimmune Diseases", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "inflammatory-diseases", "name": "Inflammatory Diseases", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}], "leader": {"name": "Patrick", "title": "head of operations"}}, {"id": "neuroscience-research", "name": "Neuroscience", "type": "therapeutic_area", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 6, "teamSizes": [], "sizeMentions": [], "snippets": [{"quote": "just to find out a little bit more about neuroscience and the DA", "date": "2025-01-13", "gongUrl": "https://app.gong.io/call?id=d36981559ab16fa615cc63c28f36976d16eb2cc6b4793cd506b1c5d2c5e88c1e", "callId": "2025-01-13_d36981559ab1", "customerName": "Magali Saint-Geniez; Magali Saint-Geniez", "internalName": "Ross Proudfoot", "customerEmail": "magali.saint-geniez@novartis.com; magali.saint-geniez@novartis.com", "internalEmail": "ross@biorender.com", "speakerId": "109613814220320311", "sizeMentions": [], "contextBefore": "... perfect.\n[Speaker 109613814220320311]: Okay.\n[Speaker 109613814220320311]: We'll do that.\n[Speaker 109613814220320311]: Just got a new headset.\n[Speaker 109613814220320311]: So, it's been on and off.\n[Speaker 109613814220320311]: It usually works but sometimes it's a little finicky.\n[Speaker 109613814220320311]: Thanks so much for taking some time.\n[Speaker 109613814220320311]: It's great to meet you.\n[Speaker 109613814220320311]: Jayden did fill me in, you know, a little bit about how you'd used BioRender in the past and sort of where you're finding it ideal in your work, but I really like to touch base with people.\n[Speaker 109613814220320311]: I have sort of all the information in terms of how licensing has gone on within Novartis thus far from our end.\n[Speaker 109613814220320311]: So I help facilitate any sort of group licensing or discount licensing for industry partners like Novartis.\n[Speaker 109613814220320311]: But from like a starting point really just an introductory call ", "contextAfter": ", and sort of your past with BioRender, whether or not you might want to do a demonstration or sort of see what the fit might be going forward.\n[Speaker 7927283921806677683]: Yeah.\n[Speaker 7927283921806677683]: Sure.\n[Speaker 7927283921806677683]: So, one thing is that I am not informed on the detail of the contract between Novartis and BioRender.\n[Speaker 7927283921806677683]: I'm a little bit aware about some of the reasons why we lost access\u2026 And I think it was some kind of data safety or cloud safety aspect, which is something again like I, there was no public when I say public company wide communication around it.\n[Speaker 7927283921806677683]: And so we actually something I don't know is I'm assuming that the data safety aspect has been addressed and there is no limitation on the content of the slide that we can prepare on BioRender.\n[Speaker 7927283921806677683]: But actually that would be something that would be very important to communicate clearly if there is ever training I...", "callTitle": "BioRender & Novartis - Follow Up Call"}, {"quote": "like the different disease areas like, you know, oncology, immunology, neuroscience, and so on cardiovascular", "date": "2025-01-10", "gongUrl": "https://app.gong.io/call?id=5d15653f349d996cc5b49ac289c82e331df8445167f7a73e534e046c1bf4f1bc", "callId": "2025-01-10_5d15653f349d", "customerName": "Samu Melkko", "internalName": "Ross Proudfoot", "customerEmail": "samu.melkko@novartis.com", "internalEmail": "ross@biorender.com", "speakerId": "233530352534476423", "sizeMentions": [], "contextBefore": "...es have used BioRender.\n[Speaker 233530352534476423]: Meanwhile, I think back in the time there was somebody from oncology and us who were both interested, but kind of there was no traction at the time from outside to move it further.\n[Speaker 233530352534476423]: And now I'm actually not updated at all what the situation is.\n[Speaker 233530352534476423]: If, you know, if, you know, Novartis, some departments have a license and how it is exactly.\n[Speaker 233530352534476423]: I just know one colleague who's using it but I don't know how and what the license situation is right now.\n[Speaker 8434859750879709595]: Yeah.\n[Speaker 8434859750879709595]: And you mentioned like oncology being interested, Are you from an adjacent group or which sort of?\n[Speaker 233530352534476423]: I'm in immunology.\n[Speaker 233530352534476423]: So we have different disease areas in research.\n[Speaker 233530352534476423]: So we have BR, it's biomedical research, and there are different units within research, ", "contextAfter": ", They are different.\n[Speaker 233530352534476423]: It's the locations are mostly in Basel in Switzerland and in Cambridge, you know, Massachusetts.\n[Speaker 233530352534476423]: Yeah.\n[Speaker 233530352534476423]: And then there's some other sites, GNF in San Diego, and so on.\n[Speaker 233530352534476423]: And then there are platforms like Biologics, Lomel, Kuwait, Screening things like this And it's you know, we of course, collaborate in project teams and everything.\n[Speaker 233530352534476423]: But each of these units have their own kind of oncology etymology head and so on.\n[Speaker 8434859750879709595]: Yeah.\n[Speaker 8434859750879709595]: So we've like I guess to give you a bit of information on how it's getting set up is there are so many different sort of small groups either purchasing or even individuals that would just kind of like sign up online.\n[Speaker 8434859750879709595]: Yeah, Whether they're using like a credit card and expensing it, or there's just kind of a flurry ...", "callTitle": "BioRender & Novartis - Intro Call"}, {"quote": "So I'm in neuroscience In neuroscience, we have an operation operations department", "date": "2025-01-09", "gongUrl": "https://app.gong.io/call?id=e4f629a603105a228bc73dbccbfdaffd25a88251115db8c7afb09dcd0de6cc87", "callId": "2025-01-09_e4f629a60310", "customerName": "Magali Saint-Geniez; Magali Saint-Geniez", "internalName": "Jaden Dankevy", "customerEmail": "magali.saint-geniez@novartis.com; magali.saint-geniez@novartis.com", "internalEmail": "jaden.dankevy@biorender.com", "speakerId": "7744876303153779367", "sizeMentions": [], "contextBefore": "... 8786806681271360026]: It might be that you will just have to apply for single licenses from the central license.\n[Speaker 8786806681271360026]: But there also might be a good case where we could do like a proof of concept with your group at a very low cost or we can have more cost effective group options for you as well.\n[Speaker 7744876303153779367]: Okay.\n[Speaker 7744876303153779367]: Yeah.\n[Speaker 7744876303153779367]: Okay.\n[Speaker 7744876303153779367]: Okay.\n[Speaker 7744876303153779367]: Okay.\n[Speaker 7744876303153779367]: Okay.\n[Speaker 7744876303153779367]: So one thing that it's important for you to appreciate is that individual user like myself although I'm a unit head and, I'm a decisional, I don't have the right to make any type of decision like that.\n[Speaker 7744876303153779367]: It would have to go through the department, operation unit Operation.\n[Speaker 7744876303153779367]: Yeah.\n[Speaker 7744876303153779367]: So operation within.\n[Speaker 7744876303153779367]: ", "contextAfter": " and that they are the one.\n[Speaker 8786806681271360026]: Okay.\n[Speaker 8786806681271360026]: Yep.\n[Speaker 8786806681271360026]: The department.\n[Speaker 8786806681271360026]: Yep.\n[Speaker 8786806681271360026]: Yep.\n[Speaker 8786806681271360026]: Yep.\n[Speaker 7744876303153779367]: Who will be in conversation with you and IT to see what are the needs from the department?\n[Speaker 7744876303153779367]: What would make the best sense?\n[Speaker 7744876303153779367]: And actually, I can tell you that I tried to re log and see whether I was automatically like added into the new Novartis BioRender license, and that's not the case.\n[Speaker 7744876303153779367]: And I said, okay, I need to let operation know, But everybody is away.\n[Speaker 7744876303153779367]: They're going to come back on Monday.\n[Speaker 8786806681271360026]: Yep.\n[Speaker 8786806681271360026]: That's not the case.\n[Speaker 8786806681271360026]: Okay.\n[Speaker 8786806681271360026]: No, no, that sounds good Is because ...", "callTitle": "Call with Novartis - Magali Saint-geniez"}, {"quote": "But in my new team in neuroscience, I know that they love to use BioRender to do presentations for medical, marketing seminar or whatever", "date": "2024-04-09", "gongUrl": "https://app.gong.io/call?id=0188070f4c6c0983d3447b5197ab58952248956c988996fec0e1e10490561c37", "callId": "2024-04-09_0188070f4c6c", "customerName": "S\u00e9bastien Reig", "internalName": "Jaden Dankevy; Ross Proudfoot", "customerEmail": "seabstien.reig@novartis.com", "internalEmail": "jaden.dankevy@biorender.com; ross@biorender.com", "speakerId": "8465446700013931599", "sizeMentions": [], "contextBefore": "...t looks like you've been pretty active.\n[Speaker 1813571857637938984]: So, looking forward to hear about your experience so far and I guess I can turn the floor to you and let you maybe introduce yourself, talk about your group and then talk about your experience with a buyer under.\n[Speaker 8465446700013931599]: So, so I, I'm working, for a novartis already 15 years, but I decided, to start a PHD and I'm also working in the lab and it's something quite\u2026 parallel of my current position.\n[Speaker 8465446700013931599]: I'm working in novartis Gene therapies.\n[Speaker 8465446700013931599]: So my experience of BioRender, it's quite new.\n[Speaker 8465446700013931599]: I discovered it in publications and I tried to connect and to do, my own figures, for my own articles.\n[Speaker 8465446700013931599]: But it's something, that is not in my novartis activity.\n[Speaker 8465446700013931599]: This is in my\u2026 research lab activity.\n[Speaker 8465446700013931599]: Okay?\n[Speaker 8465446700013931599]: ", "contextAfter": ".\n[Speaker 8465446700013931599]: So\u2026 first personally, I will need to use BioRender for continue to write my articles in my, for my lab, for my lab activity.\n[Speaker 8465446700013931599]: But I'm also interested in use BioRender more in a medical affair and\u2026 all the activity around medical affair and product lounge and trainings for my no artist activity.\n[Speaker 8465446700013931599]: Something, yeah, for both.\n[Speaker 8465446700013931599]: So\u2026 that's the point.\n[Speaker 8465446700013931599]: I know that for the moment when I talk, my new team saw that, I was using BioRender and say, okay, do you have a licensed?\n[Speaker 1813571857637938984]: This is the.\n[Speaker 8465446700013931599]: spot, do you have a license of BioRender?\n[Speaker 8465446700013931599]: So I use BioRender free for the moment.\n[Speaker 8465446700013931599]: And\u2026 novartis in my medical affair team doesn't have an agreement, doesn't have a license, but I was very interested when you contact me to say that there is...", "callTitle": "BioRender & NOVARTIS (Medical Affaires) - Intro Call"}, {"quote": "I am the head of operations, neuroscience, and we also have laboratories in Basel, cambridge and San Diego", "date": "2024-03-01", "gongUrl": "https://app.gong.io/call?id=7b31b87ac1bd97c480914d2a3847bec6652478931e5b2f06276fa50103a7fb6e", "callId": "2024-03-01_7b31b87ac1bd", "customerName": "Adam; Carlos-2 Lopez; Linda Chin; Marion Wiesmann; Petra Simic; Stefan Melly", "internalName": "Ross Proudfoot; Walid Habboub", "customerEmail": "adam.tomaszewski@novartis.com; carlos-2.lopez_ext@novartis.com; linda.chin@novartis.com; marion.wiesmann@novartis.com; petra.simic@novartis.com; stefan.melly@novartis.com; sandra.calles@novartis.com", "internalEmail": "ross@biorender.com; walid@biorender.com", "speakerId": "6630647164737669272", "sizeMentions": [], "contextBefore": "...\n[Speaker 6550203676745257136]: I just can't do on the Petra.\n[Speaker 6550203676745257136]: Yeah, I do a hand off name after.\n[Speaker 6182642638753237594]: So, Petra, I'm also head of operations for immunology, and we are located in base and I hand over to Marion\u2026 muted Marion.\n[Speaker 5598099072264006698]: Can't hear you\u2026 maybe the wrong setting, the wrong device setting the wrong Mike.\n[Speaker 7692361625660778700]: Can, can you hear?\n[Speaker 5598099072264006698]: Me now?\n[Speaker 5598099072264006698]: Yes?\n[Speaker 7692361625660778700]: I'm struggling headset off and on.\n[Speaker 7692361625660778700]: So Maria head of oncology, I'm based in base, but we have groups in as cambridge and San Diego, and on the call here are also joseppe and Sonia for each of the sites.\n[Speaker 7692361625660778700]: I don't know if wants to go next.\n[Speaker 5598099072264006698]: Maybe Marjorie.\n[Speaker 6630647164737669272]: Hi, I'm Margery Iris and I'm in cambridge.\n[Speaker 6630647164737669272]: ", "contextAfter": ".\n[Speaker 5598099072264006698]: I think Giuseppe maybe can go next.\n[Speaker 5598099072264006698]: I want to.\n[Speaker 6550203676745257136]: Good morning.\n[Speaker 6550203676745257136]: Good afternoon.\n[Speaker 6550203676745257136]: I'm a, I lead the operation in baton college perfect.\n[Speaker 5598099072264006698]: And some guitar, right?\n[Speaker 5598099072264006698]: I think she wasn't yet.\n[Speaker 3904974101244713905]: Hi.\n[Speaker 3904974101244713905]: Good morning.\n[Speaker 3904974101244713905]: Everybody.\n[Speaker 3904974101244713905]: Happy Friday.\n[Speaker 3904974101244713905]: Santa your head of operations in oncology for cambridge last year.\n[Speaker 3904974101244713905]: We did integrate the, in oncology of cambridge into oncology cambridge.\n[Speaker 3904974101244713905]: So all the licenses also got merged into one account.\n[Speaker 6550203676745257136]: Stefan is still there?\n[Speaker 5598099072264006698]: Yes, Stephan, but he mentioned that he's sick a little bit, but ...", "callTitle": "Novartis // BioRender Weekly Cadence"}, {"quote": "And neurosciences within translational medicine", "date": "2025-12-04", "gongUrl": "https://app.gong.io/call?id=9b50b1639ecf5aaed5db8d27bfc49d4f79618c5553ad975ba0cbb14c51ecdaf5", "callId": "2025-12-04_9b50b1639ecf", "customerName": "Albert Misko", "internalName": "Ross Proudfoot; Sofiya Medvezhonkova", "customerEmail": "albert.misko@novartis.com", "internalEmail": "ross@biorender.com; sofiya.m@biorender.com", "speakerId": "540529526687666601", "sizeMentions": [], "contextBefore": "...Speaker 7027995544158346041]: So from that end, like Dax, oncology, BRC, IMM, and Dari, all have full organizational like departmental licensing with us.\n[Speaker 7027995544158346041]: We did look at potentially doing that for all of BR.\n[Speaker 7027995544158346041]: But the challenges that came with that is, I think there wasn't like an overarching software budget that's managed at novartis.\n[Speaker 7027995544158346041]: Now they are independently managed by different departments.\n[Speaker 7027995544158346041]: So it works a little bit better.\n[Speaker 7027995544158346041]: It's a little bit cleaner to work at the department level rather than have everybody kind of come in with individual budgets to launch this, you know, more widespread.\n[Speaker 7027995544158346041]: So from you would fall, I guess within translational medicine.\n[Speaker 7027995544158346041]: Is that correct?\n[Speaker 7027995544158346041]: Yeah?\n[Speaker 540529526687666601]: Correct.\n[Speaker 540529526687666601]: ", "contextAfter": "?\n[Speaker 7027995544158346041]: Okay.\n[Speaker 7027995544158346041]: And, is that separate from like neurosciences as a discovery?\n[Speaker 7027995544158346041]: Okay.\n[Speaker 7027995544158346041]: So TM is sort of its own instance, is it, so to be like I'm guessing this is how it is, but it would be great to have some clarity.\n[Speaker 7027995544158346041]: Is it like every TM will sort of have an associated group with some of those discovery departments?\n[Speaker 7027995544158346041]: Like would there also be sort of a translational medicine, oncology or rare disease?\n[Speaker 7027995544158346041]: Okay?\n[Speaker 7027995544158346041]: The way it's.\n[Speaker 540529526687666601]: broken down is on the discovery side, it's by disease area.\n[Speaker 540529526687666601]: So neurosciences, immunology, cardiovascular metabolism, etc, and they work like big labs, right?\n[Speaker 540529526687666601]: It's like there's one head of all of neuroscience.\n[Speaker 540529526687666601]: And then u...", "callTitle": "BioRender & Novartis - Intro Call"}], "confidence": "medium", "status": "auto_matched"}, "children": [{"id": "neurodegeneration", "name": "Neurodegeneration", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 1, "teamSizes": [], "sizeMentions": [], "snippets": [{"quote": "And then under him there's neurodegeneration, neuroinflammation, and neuromuscular", "date": "2025-12-04", "gongUrl": "https://app.gong.io/call?id=9b50b1639ecf5aaed5db8d27bfc49d4f79618c5553ad975ba0cbb14c51ecdaf5", "callId": "2025-12-04_9b50b1639ecf", "customerName": "Albert Misko", "internalName": "Ross Proudfoot; Sofiya Medvezhonkova", "customerEmail": "albert.misko@novartis.com", "internalEmail": "ross@biorender.com; sofiya.m@biorender.com", "speakerId": "540529526687666601", "sizeMentions": [], "contextBefore": "...l medicine?\n[Speaker 7027995544158346041]: Okay.\n[Speaker 7027995544158346041]: And, is that separate from like neurosciences as a discovery?\n[Speaker 7027995544158346041]: Okay.\n[Speaker 7027995544158346041]: So TM is sort of its own instance, is it, so to be like I'm guessing this is how it is, but it would be great to have some clarity.\n[Speaker 7027995544158346041]: Is it like every TM will sort of have an associated group with some of those discovery departments?\n[Speaker 7027995544158346041]: Like would there also be sort of a translational medicine, oncology or rare disease?\n[Speaker 7027995544158346041]: Okay?\n[Speaker 7027995544158346041]: The way it's.\n[Speaker 540529526687666601]: broken down is on the discovery side, it's by disease area.\n[Speaker 540529526687666601]: So neurosciences, immunology, cardiovascular metabolism, etc, and they work like big labs, right?\n[Speaker 540529526687666601]: It's like there's one head of all of neuroscience.\n[Speaker 540529526687666601]: ", "contextAfter": ", and then there's labs under those heads that all work.\n[Speaker 7027995544158346041]: Towards that, and.\n[Speaker 540529526687666601]: Then in translational medicine, it's two divisions.\n[Speaker 540529526687666601]: One division is by sort of what you do.\n[Speaker 540529526687666601]: So I sit in tdmp which is target discovery and profiling.\n[Speaker 540529526687666601]: It's basically the medical leads that's really what we are.\n[Speaker 540529526687666601]: We're the medical leads and but then there's biomarkers, there's pkpf, pkpd, there is PCS, which is preclinical safety.\n[Speaker 540529526687666601]: There's statistics.\n[Speaker 540529526687666601]: There's you know, regulatory all of that.\n[Speaker 540529526687666601]: And then those columns are divided by therapeutic areas being neurosciences, oncology, cardiovascular medicine, that's the ones divided up?\n[Speaker 7027995544158346041]: Do you guys then you would collaborate sort of across those subgroups within a specific di...", "callTitle": "BioRender & Novartis - Intro Call"}], "confidence": "medium", "status": "auto_matched"}, "children": []}, {"id": "neuroimmunology", "name": "Neuroimmunology", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "ophthalmology-research", "name": "Ophthalmology", "type": "therapeutic_area", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "retinal-diseases", "name": "Retinal Diseases", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "nbr-basel", "name": "Novartis Biomedical Research (NBR) - Basel", "type": "site", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "nibr-cambridge", "name": "Novartis Institutes for BioMedical Research (NIBR) - Cambridge, MA", "type": "site", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "nibr-emeryville", "name": "NIBR - Emeryville, CA", "type": "site", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}], "leader": {"name": "Fiona Marshall", "title": "President, Biomedical Research"}}, {"id": "development", "name": "Development", "type": "division", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "global-drug-development", "name": "Global Drug Development", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "oncology-development", "name": "Oncology Development", "type": "therapeutic_area", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "cardiovascular-development", "name": "Cardiovascular Development", "type": "therapeutic_area", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "immunology-development", "name": "Immunology Development", "type": "therapeutic_area", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "neuroscience-development", "name": "Neuroscience Development", "type": "therapeutic_area", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "clinical-pharmacology-safety-sciences", "name": "Clinical Pharmacology & Safety Sciences", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "pharmacokinetics-pharmacodynamics", "name": "Pharmacokinetics & Pharmacodynamics", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "clinical-safety", "name": "Clinical Safety", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "translational-medicine", "name": "Translational Medicine", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 3, "teamSizes": [], "sizeMentions": [], "snippets": [{"quote": "So from you would fall, I guess within translational medicine", "date": "2025-12-04", "gongUrl": "https://app.gong.io/call?id=9b50b1639ecf5aaed5db8d27bfc49d4f79618c5553ad975ba0cbb14c51ecdaf5", "callId": "2025-12-04_9b50b1639ecf", "customerName": "Albert Misko", "internalName": "Ross Proudfoot; Sofiya Medvezhonkova", "customerEmail": "albert.misko@novartis.com", "internalEmail": "ross@biorender.com; sofiya.m@biorender.com", "speakerId": "7027995544158346041", "sizeMentions": [], "contextBefore": "...ndardized across those departments in terms of people sharing out.\n[Speaker 7027995544158346041]: You know, if you're talking about this, it's communicated like this and sort of building out that repository as well.\n[Speaker 7027995544158346041]: So from that end, like Dax, oncology, BRC, IMM, and Dari, all have full organizational like departmental licensing with us.\n[Speaker 7027995544158346041]: We did look at potentially doing that for all of BR.\n[Speaker 7027995544158346041]: But the challenges that came with that is, I think there wasn't like an overarching software budget that's managed at novartis.\n[Speaker 7027995544158346041]: Now they are independently managed by different departments.\n[Speaker 7027995544158346041]: So it works a little bit better.\n[Speaker 7027995544158346041]: It's a little bit cleaner to work at the department level rather than have everybody kind of come in with individual budgets to launch this, you know, more widespread.\n[Speaker 7027995544158346041]: ", "contextAfter": ".\n[Speaker 7027995544158346041]: Is that correct?\n[Speaker 7027995544158346041]: Yeah?\n[Speaker 540529526687666601]: Correct.\n[Speaker 540529526687666601]: And neurosciences within translational medicine?\n[Speaker 7027995544158346041]: Okay.\n[Speaker 7027995544158346041]: And, is that separate from like neurosciences as a discovery?\n[Speaker 7027995544158346041]: Okay.\n[Speaker 7027995544158346041]: So TM is sort of its own instance, is it, so to be like I'm guessing this is how it is, but it would be great to have some clarity.\n[Speaker 7027995544158346041]: Is it like every TM will sort of have an associated group with some of those discovery departments?\n[Speaker 7027995544158346041]: Like would there also be sort of a translational medicine, oncology or rare disease?\n[Speaker 7027995544158346041]: Okay?\n[Speaker 7027995544158346041]: The way it's.\n[Speaker 540529526687666601]: broken down is on the discovery side, it's by disease area.\n[Speaker 540529526687666601]: So neurosciences...", "callTitle": "BioRender & Novartis - Intro Call"}, {"quote": "Have you worked with translational medicine at all? So, this would be Evan Beckman's group and Courtney Horvath.", "date": "2025-11-05", "gongUrl": "https://app.gong.io/call?id=cebf2186536fb0a794dd7ed70022fed95b6107edc9abf012ee6cc8b981a91bc9", "callId": "2025-11-05_cebf2186536f", "customerName": "Renee Bergeron", "internalName": "Ross Proudfoot; Sofiya Medvezhonkova", "customerEmail": "renee.bergeron@novartis.com", "internalEmail": "ross@biorender.com; sofiya.m@biorender.com", "speakerId": "3699100416717219889", "sizeMentions": [], "contextBefore": "...o I think what it will be is if groups continue to bring it along.\nSo on slide decks, as you probably know, probably all of corporate America lives on slide decks.\nAnd as scientists, we're not the most visually exciting.\nI mean, I can't tell you how many words, we should probably count, how many words per slide we use because I've seen some with, you know.\nAnd I hear it's even like, I mean, I see it too.\nI work with industry scientists a lot, but it's like the further away you get from schematics or publication type visuals, the less visual.\nIt gets like the communication at the corporate level tends to be even more wordy, right?\nSo it's something that you guys are always trying to combat and simplify.\nPeople don't read it right?\nMyself included, right?\nSo, I was just fascinated by the concept of being able to do what you guys were showing without having that artistic or graphic design base that said, you're going to ask me well, who does make those decisions?\nI just think it's crazy.\n", "contextAfter": "\nI have not worked with them.\nI haven't really worked with translational.\nI know you guys are an arm of translational medicine, correct?\nThat's right?\nYeah.\nWhat I've been told from the few people in translational that have sort of bought individual licenses and said, hey, I need one.\nI'm going to use it regularly and purchase the licenses that it's such a large department that it probably makes sense to look almost at the sub department level if there's budget holders.\nSo to me, PCS might be a more immediate group to take advantage of this, that would cover yourself and team members.\nAnd so.\nSomebody just walk me through this.\nSomebody brought you in, set up a seminar within PCS, but then kind of said, oh, well, we don't make decisions.\nAnd so now you guys are trying to find in PCS, how to get back?\nSo, it was a scientist champion that had worked with, let me grab, but\u2026 I think she just even had.\nI'm not trying to get you.\nI'm not trying to get anybody in trouble.\nI'm trying to get yo...", "callTitle": "BioRender & Novartis - Follow Up Call"}, {"quote": "So those are all from translational medicine currently", "date": "2025-04-16", "gongUrl": "https://app.gong.io/call?id=0ed32b9f3917ab20a34cd65d8d0318286c374126df243c1396c80ca24384a4fb", "callId": "2025-04-16_0ed32b9f3917", "customerName": "Adam Tomaszewski; Adam Tomaszewski; Linda Chin", "internalName": "Ross Proudfoot; Tim Fung", "customerEmail": "adam.tomaszewski@novartis.com; adam.tomaszewski@novartis.com; linda.chin@novartis.com", "internalEmail": "ross@biorender.com; tim@biorender.com", "speakerId": "2567351405035696877", "sizeMentions": [], "contextBefore": "...79094350391382]: Especially if we're looking at like department by department, how many free users they have along with.\n[Speaker 1821801272283730809]: Users.\n[Speaker 8312379094350391382]: But definitely don't use those total.\n[Speaker 8312379094350391382]: Like when there's like 800 users, I wouldn't say that's kind of going to be our source of truth going forward, but I'll look into this and make sure, and.\n[Speaker 1821801272283730809]: Then there's one Guy that has an individual paid license.\n[Speaker 1821801272283730809]: So I'm not sure.\n[Speaker 1821801272283730809]: Yeah.\n[Speaker 8312379094350391382]: So that would have been something that was purchased on our website outside of any sort of novartis licensing.\n[Speaker 8312379094350391382]: Okay?\n[Speaker 1821801272283730809]: He's in PKS.\n[Speaker 1821801272283730809]: I wonder\u2026 if we have other people in that group if.\n[Speaker 2567351405035696877]: I'm checking with the PKS PCS and cis guys.\n[Speaker 2567351405035696877]: ", "contextAfter": ".\n[Speaker 2567351405035696877]: So I hope that we received their feedback maybe still today or tomorrow.\n[Speaker 2567351405035696877]: So Courtney already reached out.\n[Speaker 2567351405035696877]: Okay?\n[Speaker 1821801272283730809]: So, he's not going to be on your list.\n[Speaker 1821801272283730809]: He's on Ross's list, the individual paid license.\n[Speaker 1821801272283730809]: He's not part of the org paid.\n[Speaker 2567351405035696877]: That's also weird that he says it's on the individual one.\n[Speaker 2567351405035696877]: Okay.\n[Speaker 2567351405035696877]: Let's see, let's see what Courtney will say, and then we can still ask her about this Guy, sure.\n[Speaker 1821801272283730809]: Okay.\n[Speaker 1821801272283730809]: And.\n[Speaker 8312379094350391382]: That's external to biomedical research or is that it's translated?\n[Speaker 2567351405035696877]: It's part, it's part of biomedical research.\n[Speaker 2567351405035696877]: So we have, so TMS is the translation medicine ...", "callTitle": "BioRender - Novartis Central BR Renewal"}], "confidence": "medium", "status": "auto_matched"}, "children": [{"id": "biomarker-development", "name": "Biomarker Development", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "precision-medicine", "name": "Precision Medicine", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}], "leader": {"name": "Evan Beckman", "title": null}}, {"id": "regulatory-affairs-development", "name": "Regulatory Affairs", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "development-operations", "name": "Development Operations", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "clinical-operations", "name": "Clinical Operations", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "clinical-data-management", "name": "Clinical Data Management", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}], "leader": {"name": "Shreeram Aradhye", "title": "Chief Medical Officer & Global Head Development"}}, {"id": "pharmaceutical-sciences", "name": "Pharmaceutical Sciences (Technical R&D)", "type": "division", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "small-molecule-development", "name": "Small Molecule Development", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "pharmaceutical-development", "name": "Pharmaceutical Development", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "analytical-sciences-sm", "name": "Analytical Sciences", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "biologics-development", "name": "Biologics Development", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "biologics-process-development", "name": "Process Development", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "analytical-sciences-bio", "name": "Analytical Sciences - Biologics", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "cell-gene-therapy-development", "name": "Cell & Gene Therapy Development", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "car-t-manufacturing", "name": "CAR-T Manufacturing Sciences", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "gene-therapy-manufacturing", "name": "Gene Therapy Manufacturing", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "pharmaceutical-sciences-basel", "name": "Pharmaceutical Sciences - Basel", "type": "site", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "pharmaceutical-sciences-east-hanover", "name": "Pharmaceutical Sciences - East Hanover, NJ", "type": "site", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "data-digital-technology", "name": "Data & Digital Technology (R&D)", "type": "division", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "ai-machine-learning", "name": "AI & Machine Learning", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "generative-ai", "name": "Generative AI", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "drug-discovery-ai", "name": "AI for Drug Discovery", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "bioinformatics-computational-biology", "name": "Bioinformatics & Computational Biology", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "genomics-bioinformatics", "name": "Genomics & Bioinformatics", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "systems-biology", "name": "Systems Biology", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "data-sciences", "name": "Data Sciences", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "real-world-evidence", "name": "Real-World Evidence", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "clinical-data-analytics", "name": "Clinical Data Analytics", "type": "team", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}]}, {"id": "platform-technologies", "name": "Platform Technologies & Capabilities", "type": "division", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "radioligand-therapy", "name": "Radioligand Therapy", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "car-t-platform", "name": "CAR-T Cell Therapy Platform", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "gene-therapy-platform", "name": "Gene Therapy Platform", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "rna-therapeutics", "name": "RNA Therapeutics", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "targeted-protein-degradation", "name": "Targeted Protein Degradation", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "antibody-engineering", "name": "Antibody Engineering", "type": "department", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}, {"id": "global-rd-sites", "name": "Global R&D Sites", "type": "division", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": [{"id": "basel-switzerland", "name": "Basel, Switzerland (Global HQ & Primary R&D Hub)", "type": "site", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "cambridge-ma", "name": "Cambridge, MA, USA", "type": "site", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "east-hanover-nj", "name": "East Hanover, NJ, USA", "type": "site", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "emeryville-ca", "name": "Emeryville, CA, USA", "type": "site", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "hyderabad-india", "name": "Hyderabad, India", "type": "site", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "shanghai-china", "name": "Shanghai, China", "type": "site", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}, {"id": "morris-plains-nj", "name": "Morris Plains, NJ, USA (CAR-T)", "type": "site", "level": 0, "sites": [], "notes": "", "gongEvidence": {"matchedEntities": [], "matchedContacts": [], "totalMentions": 0, "teamSizes": [], "sizeMentions": [], "snippets": [], "confidence": "none", "status": "unverified"}, "children": []}]}]}}